The company applies its design concepts and technological innovations to the discovery of small molecules, with a focus on monovalent molecular glues with its Allo-Glue platform, and to the design and engineering of novel classes of precision biologics and cytokine-based immunotherapies with its A-Kine platform.

Orionis is advancing a deep and diversified pipeline of drug modalities, including agents that engage components of the adaptive and innate immune systems with high precision, creating new avenues for the development of single agent-effective therapies for patients with cancer and other diseases.